January 2008 in “Projeto: revista mensal de arquitetura” Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
153 citations
,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
April 2012 in “Cancer research” Blocking mTORC1 may help prevent skin cancer by stopping the growth of certain skin stem cells.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
15 citations
,
May 2021 in “British journal of dermatology/British journal of dermatology, Supplement” Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
1 citations
,
May 2022 in “Frontiers in Pharmacology” Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
24 citations
,
November 2013 in “Trends in pharmacological sciences” Increasing ABC transporters in hair follicles may prevent chemotherapy-induced hair loss.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
January 2024 in “Wiadomości Lekarskie” Cell therapy is advancing with stem cell transplants and genetically modified cells improving treatment for diseases like cancer and autoimmune disorders.
October 2022 in “Amplla Editora eBooks” Tocilizumab might be an effective treatment for COVID-19.
77 citations
,
July 2020 in “European Journal of Clinical Pharmacology” Blocking the virus's entry into cells by targeting certain pathways could lead to early COVID-19 treatments.
5 citations
,
July 1991 in “Irish Journal of Medical Science (1971 -)” Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
January 2009 in “Epsilon: Revista de la Sociedad Andaluza de Educación Matemática "Thales"” A CCS patient with severe complications was successfully treated using combined therapies.